Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:44:57 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:FBIO - FORTRESS BIOTECH INC - https://fortressbiotech.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FBIO - Q0.13.03·6.000.13.27+0.3411.6627.01,8812,1863.02  3.27  3.004.53  1.32519:37:22Jan 1315 min RT 2¢

Recent Trades - Last 10 of 2186
Time ETExPriceChangeVolume
19:37:22Q3.270.341
19:15:55Q3.270.343
19:13:38Q3.270.343
19:13:10Q3.270.343
19:12:08Q3.270.345
18:24:09Q3.200.272
18:24:09Q3.200.27100
18:24:09Q3.200.27185
18:24:09Q3.210.282
18:24:09Q3.270.342,401

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-13 07:45U:FBIONews ReleaseFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO(TM) (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
2025-12-15 08:00U:FBIONews ReleaseFortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
2025-12-10 08:30U:FBIONews ReleaseJourney Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi(TM) (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
2025-11-14 08:30U:FBIONews ReleaseFortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
2025-11-12 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
2025-11-06 07:00U:FBIONews ReleaseAvenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
2025-11-05 08:30U:FBIONews ReleaseJourney Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
2025-10-24 08:30U:FBIONews ReleaseJourney Medical Corporation Reports Combined Emrosi(TM) (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
2025-10-21 08:31U:FBIONews ReleaseFortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
2025-10-08 08:31U:FBIONews ReleaseJourney Medical Corporation to Participate in October 2025 Investor Conferences
2025-10-01 08:06U:FBIONews ReleaseFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing
2025-10-01 08:01U:FBIONews ReleaseFortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
2025-09-03 08:31U:FBIONews ReleaseJourney Medical Corporation to Participate in September 2025 Investor Conferences
2025-09-02 08:30U:FBIONews ReleaseFortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-18 08:30U:FBIONews ReleaseJourney Medical Corporation to Present at the Emerging Growth Conference
2025-08-14 16:05U:FBIONews ReleaseFortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
2025-08-12 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
2025-08-07 08:30U:FBIONews ReleaseJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
2025-08-05 16:01U:FBIONews ReleaseJourney Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
2025-07-14 08:30U:FBIONews ReleaseJourney Medical Corporation Announces Expanded Payer Coverage for Emrosi(TM)